Background/Aims: Angiotensin II (Ang II) has been shown to promote cardiac remodeling during the process of hypertrophy. Myosin light chain kinase (MLCK), a specific kinase for the phosphorylation of myosin light chain 2 (MLC2), plays an important role in regulating cardiac muscle contraction and hypertrophy. However, whether Ang II could facilitate cardiac hypertrophy by altering the expression of MLCK remains unclear. This study aimed to investigate this effect and the underlying mechanisms. Methods: Cardiac hypertrophy was induced via pressure overload in rats, which were then evaluated via histological and biochemical measurements and echocardiography. Angiotensin-converting enzyme inhibitor (ACEI) was used to inhibit Ang II. Neonatal rat cardiomyocytes were stimulated with Ang II to induce hypertrophy and were treated with a matrix metalloproteinase 9 (MMP9) inhibitor. Myocyte hypertrophy was evaluated using immunofluorescence and qRT-PCR. Degradation of recombinant human MLCK by recombinant human MMP9 was tested using a cleavage assay. The expression levels of MLCK, MLC2, phospho-myosin light chain 2 (p-MLC2), myosin phosphatase 2 (MYPT2), and calmodulin (CaM) were measured using western blotting. Results: ACEI improved cardiac function and remodeling and increased the levels of MLCK and p-MLC2 as well as reduced the expression of MMP9 in pressure overload-induced cardiac hypertrophy. Moreover, the MMP9 inhibitor alleviated myocyte hypertrophy and upregulated the levels of MLCK and p-MLC2 in Ang II-induced cardiomyocyte hypertrophy. Recombinant human MLCK was concentration-and time-dependently degraded by recombinant human MMP9 in vitro, and this process was prevented by the MMP9 inhibitor. Conclusion: Our results suggest that Ang II is involved in the degradation of MLCK in pressure overload-induced cardiac hypertrophy and that this process was mediated by MMP9.
Introduction
Cardiac hypertrophy is a compensatory process of the heart to enhance cardiac output to adapt to various pathological conditions such as hypertension, aortic stenosis, valvular dysfunction, and myocardial infarction, and this pathological cardiac hypertrophy will eventually progress to heart failure [1, 2] . Chronic pressure overload could lead to cardiac hypertrophy and is closely related to the autocrine release of Angiotensin II (Ang II) from the myocardium in response to an abnormal mechanical stress [3] [4] [5] . Additionally, both myocardial remodeling in patients with heart failure and cardiac hypertrophy in rats with ascending aortic banding could be significantly attenuated or reversed by inhibiting the renin-angiotensin system [6, 7] . However, it is still not fully understood how Ang II influences cardiac remodeling in response to pressure overload.
Myosin light chain 2 (MLC2) is an important component of myosin, and it has a serine residue at its N-terminus, which is specifically phosphorylated by myosin light chain kinase (MLCK). However, phosphorylation of MLC2 is a result of a dynamic balance between the opposing activities of MLCK and myosin light chain phosphatase (MLCP) [8, 9] . MLCP can dephosphorylate MLC2 in the heart, and it comprises distinct subunits, including myosin phosphatase 2 (MYPT2), an isoform of myosin-binding regulatory subunits, and a catalytic subunit similar to type 1 protein phosphatase δ isoform (PP1cδ) [10] . Recent studies on genetic mouse models have shown that phosphorylated MLC2 not only plays a role in cardiac muscle contraction but is also crucial in regulating cardiac hypertrophy [11] [12] [13] [14] .
Acute administration of both cultured cardiac myocytes and the rat heart with Ang II can lead to increased phosphorylation of MLC2, and this process can be mediated by MLCK, which could specifically promote Ang II-induced sarcomere organization at an early stage [15] . Meanwhile, adenovirus-mediated overexpression of MYPT2 and PP1cδ in cultured cardiomyocytes could reduce the levels of phosphorylated MLC2 following stimulation with A23187 and block the Ang II-induced sarcomere organization in a short time [16] . This evidence suggests that phosphorylated MLC2 may be involved in Ang II-induced cardiac remodeling.
MLCK is the predominant kinase for MLC2, and previous studies have revealed that recombinant MLCK phosphorylates endogenous MLC2 in a Ca 2+ /calmodulin-dependent manner [17, 18] . However, recent studies suggested that the catalytic activity of MLCK does not appear to be regulated by Ca 2+ /calmodulin [19, 20] . Several matrix metalloproteinases (MMPs), especially matrix metalloproteinase 9 (MMP9), have been reported to play an important role during the progression of cardiac disease by regulate the expression of proteins and degradation of kinases [21] [22] [23] . Angiotensin-converting enzyme 2 knockout (ACE2KO) mice have increased Ang II levels during postnatal development, and their expression levels of MMP-9 mRNA were higher in ACE2KO mice than in wild type (WT) mice at 10 weeks of age [24, 25] . Whether MMP9 plays a part in MLCK degradation in cardiac remodeling remains unclear.
Based on these available data, we speculated that Ang II is involved the in degradation of MLCK in pressure overload-induced cardiac hypertrophy and that this process was mediated by MMP9. In this study, we aimed to elucidate these issues by establishing a pressure overload-induced cardiac hypertrophy rat model and an Ang II-induced cardiomyocyte hypertrophy model. 
Materials and Methods

Reagents
Aortic banding (AB)
Rats were anesthetized with chloral hydrate (300 mg/kg, i.p.). Then, pressure overload was induced as previously described by tying a 7-0 silk suture around the abdominal aorta at the suprarenal level over a 22-gauge blunted-needle, which causes occlusion of the aorta [26] [27] [28] . The needle was quickly removed resulting in partial stenosis of the aortic lumen. In the sham group, rats underwent the procedure without aortic constriction and served as controls. After the operation, Doppler analysis was performed to verify whether the aorta had been constricted properly.
Administration of angiotensin-converting enzyme inhibitor (ACEI)
The rats were randomly allotted to 3 groups as follows: (1) controls undergoing sham-operation; (2) AB without treatment; and (3) AB treated with an ACEI. The ACEI (captopril, 200 mg/kg body weight/day) was dissolved in drinking water for ease of intake. The rats kept receiving drugs from postoperative day 5 to the end of the eighth week after the surgical procedure. The first two groups were given the same water but without any drug.
Echocardiography
Transthoracic echocardiography was performed on rats under 1.5-2% inhaled isoflurane anesthesia using a MyLab 30CV ultrasound system (Biosound Esaote, Inc., Indianapolis, Indiana, USA) with a 15-MHz transducer probe as reported previously [26, 29] . M-mode echocardiograms were collected utilizing standard echocardiography techniques from short-axis views at the mid-papillary muscle level of the LV. The LV wall thickness at end-diastole at the level of intraventricular septum and the posterior wall (IVSd and LVPWd, respectively) and end-systolic and end-diastolic dimension of the LV (LVESD and LVEDD, respectively) were measured in at least three consecutive heartbeats in accordance with the American Society of Echocardiography guidelines. Simoson's method of disks was used to determine the LV endsystolic and end-diastolic volumes (LVESV and LVEDV, respectively). The LV ejection fraction and fractional shortening (LVEF and LVFS, respectively) were calculated as follows: LVEF (%)=(LVEDV-LVESV)/LVEDV × 100%, and LVFS (%)=(LVEDD-LVESD)/LVEDD × 100%).
Histological analysis
After echocardiography at the end of the fourth week, rats were weighed and then sacrificed for heart removal. The weight of hearts and lungs and the length of tibias were measured separately [30] . The excised hearts were arrested in diastole by dipping the hearts in a 1 mmol l KCl solution, fixing the organs in 4% paraformaldehyde at room temperature and embedding the hearts in paraffin 24 hours later. Then, the heart tissues were sliced into 5-µm sections for staining with hematoxylin and eosin (HE) and Masson's trichrome to measure the myocyte cross-sectional area (CSA) and determine the degree of myocardial fibrosis [31, 32] . Stained sections were captured using a microscope and the images were analyzed using Image-Pro Plus version 6.0 (Media Cybernetics, Bethesda, MD, USA). There was a minimum of 100 myocytes from each group that were measured. More than 50 fields from the LV interstitial and perivascular regions in each group were measured to calculate the mean percentage volume of fibrosis. Cardiomyocyte culture and treatment with an MMP9 inhibitor As reported previously, neonatal rat cardiomyocytes (NRCMs) were isolated from the hearts of SD rat pups on postnatal days 1-2, and were cultured to greater than 97% purity, as confirmed by Inverted phasecontrast microscopy and immunocytochemical staining (the data was not shown in the article) [26, 33, 34] . Briefly, SD rats were sacrificed by swift decapitation, and the hearts were excised and minced immediately. The heart tissues were digested in a solution containing 0.08% collagenase type II and 0.125% trypsin, and the supernatant was collected. Then, cardiomyocytes were enriched via differential attachment, plated and cultured in 6-well plates with DMEM/F12 medium (Gibco, Grand Island, NY, USA) containing 15% FBS, 1% penicillin/streptomycin and 0.1 mM BrdU (Sigma-Aldrich, St. Louis, MO, USA). After 48 hours, the culture medium was replaced with serum-free DMEM/F12 medium for 24 hours. Afterwards, the cardiomyocytes were randomly assigned into 3 groups followed by different treatments for 48 hours; these groups comprised the following: (1) PBS; (2) 10 -6 mol/L AngII; and (3) 10 -6 mol/L AngII + 10 -6 mol/L MMP9 inhibitor (SB-3CT) [35, 36] . The volumes of these treatments were equal among groups.
Immunofluorescence staining
For immunofluorescence analyses, cardiomyocytes were seeded onto glass coverslips. When the treatments were completed, the cardiomyocytes were washed with PBS and fixed with 4% paraformaldehyde for 20 min at room temperature. Then, the cardiomyocytes were permeabilized for 40 minutes with 0.1% Triton X-100 in PBS and incubated with α-actinin (1:100 dilution) overnight at 4 °C. After washes with PBS, the cardiomyocytes were incubated with anti-mouse secondary antibodies for 40 min at 37 °C. The cardiomyocytes were subsequently mounted in ProLong Antifade with 4', 6-diamidino-2-phenylindole dihydrochloride (DAPI) (Invitrogen, Carlsbad, CA, USA). Images were captured using a fluorescence microscope (Olympus, Tokyo, Japan). Each group had at least 50 cardiomyocytes measured using Image-Pro Plus 6.0 (Media Cybernetics, Bethesda, MD, USA) to determine the cell surface area.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA from frozen rat heart tissue and NRCMs was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) as previously described [37] [38] [39] [40] . Then, cDNA was synthesized using a Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim,Germany). The expression levels of the target genes were determined using qRT-PCR, which was conducted using the SYBR Green PCR Master Mix (Roche, Mannheim,Germany). The results were normalized against GAPDH gene expression. The sequences of primers utilized for amplification were as follows: (1) 
Cleavage assay
Recombinant human MLCK was incubated with recombinant human MMP-9 in vitro in reaction buffer (20 μL of the total volume; 50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2) at 37 °C with or without MMP9 inhibitor (SB-3CT, 10 -6 mol/L) as previously described [35, 36, 41] . Then, the samples were used for western blotting to measure recombinant human MLCK and degraded recombinant human MLCK.
Western blotting
The western blotting procedure was performed as reported previously [26, 42, 43] . The LV tissue samples were extracted to obtain a protein solution in RIPA lysis buffer. A BCA Protein Assay Kit was utilized to determine the protein concentration proteins. Extracts containing 20 µg of protein per sample were resolved using SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA, USA). The membranes were blocked with either 5% BSA (for p-MLC2) or 5% fat-free milk (for other proteins) in TBST for 1 hour under the room temperature followed by incubation with the indicated primary antibodies in TBST overnight at 4 °C (1:2000 dilution of MLCK, 1:1000 dilution of p-MLC2, 1:15 dilution of MLC2, 1:500 dilution of MYPT2, 1:2000 dilution of calmodulin, 1:1000 dilution of MMP9, and 1:10000 dilution of GAPDH). After that, the blots were incubated with corresponding horseradish peroxidase conjugated secondary antibodies in TBST for 30 minutes at room temperature. Finally, the target bands were visualized and quantified using a FluorChem E System (Cell Biosciences, Santa Clara, CA, USA) and normalized against GAPDH to determine the protein expression levels in each sample.
Statistical analysis
All data are expressed as the means±SD, which was calculated from the average measurements in each group. Intergroup comparisons were performed using one-way analysis of variance (ANOVA) followed by a post hoc Tukey's test. Student's t-test was applied to compare between two groups. A probability value of P<0.05 was set to indicate that the differences had statistical significance. Data and statistical analysis were conducted using IBM SPSS statistics version 20 (Chicago, IL, USA).
Results
ACEI improved pressure overload-induced cardiac dysfunction and myocardial remodeling
Four weeks after surgery, AB resulted in heart failure with a severe LV dilatation and cardiac dysfunction as indicated by echocardiography with increases in the LVEDD and LVEDV and reductions in LVEF and LVFS in comparison with the sham group ( Fig. 1 A and Table 1 ). These echocardiographic parameters had a significant trend to reverse in the treatment group compared with these values in the AB group (Table 1) . Neither IVSd and LVPWd had a significant difference between the sham and AB groups, but both values in the AB+ACEI group were significantly larger than those in the AB group (Table 1) . Meanwhile, cardiac hypertrophy induced by pressure overload in the AB group was demonstrated by the increased ratios of heart weight/body weight (HW/BW), lung weight/body weight (LW/ BW), and heart weight/tibial length (HW/TL) compared with the sham group; however, these ratios decreased significantly in the AB+ACEI group ( Fig. 1 B-D) .
Pathological analysis, including cardiac myocyte hypertrophy and fibrosis, was performed using HE and Masson staining to determine whether ACEI treatment could attenuate pressure overload-induced myocardial remodeling. Myocyte CSA and the fibrotic percentage in the AB group was larger than in the sham group (Fig. 2 A-C) . Drugs treatment caused a significant reduction in myocyte CSA and the fibrotic percentage compared with them in the AB group (Fig. 2 A-C) . These evidence suggested that ACEI could mitigate pressure overload-induced myocardial remodeling via decreased cardiac myocyte CSA and fibrosis. The relative mRNA levels of cardiac hypertrophic markers such as ANP, BNP and β-MHC were higher in the AB group than in the sham group, and these levels declined in AB group treated with ACEI as expected (Fig. 1 E-G) . Taken together, these results showed that ACEI could significantly improve pressure overload-induced cardiac dysfunction and myocardial remodeling. 
ACEI increased MLCK but not MLCP expression in the cardiac pressure overload model
Western blotting was performed to detect the expression levels of MLCK and MYPT2. The expression of MLCK was decreased in the AB group compared with the sham group (Fig.  3 A and B) . Drug intake elevated the expression of MLCK (Fig. 3 A and B) . However, such changes in the expression level of MYPT2 were not recognized, and the differences among all the groups were deemed insignificant ( Fig. 3 A and D) .
The phosphorylation level was also measured using western blotting, which quantified the expression of MLC2 and p-MLC2 and was used to calculate the percentage of phosphorylated MLC2. Analytic results revealed that the phosphorylation levels in the AB group with heart failure were lower than those in the sham group (Fig. 3 A and C) . In the AB+ACEI group, the phosphorylation level presented a marked increase (Fig. 3 A and  C) , which demonstrated that ACEI enhanced the phosphorylation of MLC2 in the pressure overload-induced failing heart.
In addition, AB led to increased expression of CaM compared with the sham group ( Fig.  3 A and E) . The expression level in the groups treated with ACEI was significantly reduced (Fig. 3 A and E) , which indicated that ACEI affected the expression of CaM in the pressure overload-induced cardiac hypertrophy. Remarkably, we found that the protein levels of MMP9 in the AB group were higher than those in the sham and treatment groups (Fig. 3 A and F) , which implied that MMP9 may be involved in the mechanism by which Ang II regulates MLCK.
MMP9 inhibitor alleviated Ang II-induced cardiomyocyte hypertrophy
To define the role of MMP9 in Ang II-induced cardiac remodeling, we established a cardiomyocyte hypertrophic model via stimulation with Ang II and applied an MMP9 inhibitor to suppress MMP9 activity. Cardiomyocyte hypertrophy induced by Ang II was confirmed by the increased cell surface area and relative mRNA expression levels of ANP, BNP and β-MHC. The results showed that treatment with the MMP9 inhibitor significantly decreased the Ang II-induced increases in cardiomyocyte size (Fig. 4 A and B) . Additionally, the MMP9 inhibitor markedly attenuated the upregulation of ANP, BNP and β-MHC mRNA expression in the presence of Ang II (Fig. 4 C-E) . These data demonstrated that MMP9 facilitated cardiomyocyte hypertrophy in response to stimulation by Ang II.
MMP9 inhibitor upregulated MLCK expression in Ang II-induced cardiomyocyte hypertrophy
To further determine whether MMP9 contributes to Ang II-mediated regulation of MLCK, we detected MLCK protein in Ang II-induced hypertrophic cardiomyocytes in the 
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Cellular Physiology and Biochemistry presence or absence of MMP9 inhibitor using western blotting. MMP9 was suppressed by the MMP9 inhibitor as demonstrated by western blotting (Fig. 5 A and F) . Furthermore, the levels of p-MLC2, MLC2, MYPT2 and CaM were also detected. Both MLCK and p-MLC2/MLC2 were reduced significantly in Ang II-induced hypertrophic cardiomyocytes without MMP9 inhibitor treatment, but this trend become less marked when the MMP9 inhibitor was added (Fig. 5 A-C) . The expression level of MYPT2 showed no obvious alterations in cardiomyocytes with or without MMP9 inhibitor treatment (Fig. 5 D) . In addition, the expression level of CaM was not affected by the MMP9 inhibitor (Fig. 5 E) .
Recombinant human MMP9 cleaves recombinant human MLCK in vitro
Recombinant human MLCK was incubated with recombinant human MMP9 in vitro in reaction buffer at 37 °C to examine whether recombinant human MLCK could be degraded as a substrate for recombinant human MMP9. Western blotting confirmed the degraded recombinant human MLCK fragment and further showed that recombinant human MLCK was degraded by recombinant human MMP9 in incubation time-dependent and concentrationdependent manners (Fig. 6 A and B) . Consistently, the degradation of recombinant human MLCK by recombinant human MMP9 was prevented in the presence of MMP9 inhibitor in vitro (Fig. 6 C) . 
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Discussion
MLC2, an important component of myosin, could be phosphorylated and dephosphorylated by MLCK and MLCP, respectively, and its phosphorylation play a direct role in regulating cardiac muscle contraction, function, and disease [44] [45] [46] . Previous studies have shown that acute stimulation of cultured cardiomyocytes and the rat heart with Ang II could increase MLCK, phosphorylated MLC2, and sarcomere organization, and cultured cardiomyocytes overexpressing MYPT2 and PP1cδ could rapidly inhibit Ang II-induced sarcomere organization [15, 16] . However, whether Ang II affects MLC2 phosphorylation during the course of cardiac hypertrophy and heart failure remains unknown. In the present study, we established pressure overload-induced cardiac hypertrophy and Ang IIinduced cardiomyocyte hypertrophy models and demonstrated that (i) inhibition of Ang II could improve cardiac remodeling and cardiomyocyte hypertrophy; (ii) inhibition of Ang II enhanced the phosphorylation level of MLC2 by increasing MLCK but not MLCP; (iii) inhibition of Ang II decreased the expression of MMP9; (iv) inhibition of MMP9 alleviated Ang II-induced reduction of MLCK; and (v) recombinant human MMP9 degrades recombinant 
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human MLCK in vitro. Taken together, this study suggests for the first time that Ang II could decrease MLC2 phosphorylation in pressure overload-induced cardiac hypertrophy and that this process involves MMP9-mediated MLCK degradation, which may provide novel insight into the mechanisms of pathological cardiac hypertrophy. Ang II contributes to cardiac remodeling during the development of cardiac hypertrophy and heart failure, and this process could be attenuated or reversed markedly by inhibiting Ang II [7, [47] [48] [49] [50] . In this study, we observed that inhibition of Ang II could alleviate myocardial remodeling and improve cardiac function in pressure overload-induced cardiac hypertrophy, which we confirmed using echocardiography, histological analysis and qRT-PCR. Pressure overload caused left ventricular (LV) dilatation with increased LVESD, LVEDD, LVESV and LVEDV as well as cardiac dysfunction with drastic decreases in LVEF and LVFS, which indicated that eccentric and decompensatory hypertrophy had emerged in the AB group.
MLC2, a component of myosin, wraps around myosin essential light chain (MLC1) together around the myosin neck domain in an anti-parallel manner [51] . MLC2 has been distinguished from MLC1 by a serine residue in the N-terminus of the peptide that can be phosphorylated by MLCK, which causes the transition of MLC2 from a compacted form to an elongated form [52] . MLCP is the phosphatase for MLC2 and consisting of three subunits-MYPT2, PP1cδ and a small subunit of undefined function [10] . In the present study, reductions of MLCK and MLC2 phosphorylation were observed in rat hearts subjected to pressure overload. Meanwhile, we found that inhibiting Ang II could ameliorate this trend in reduced expression. However, acute administration of cultured cardiomyocytes and rat hearts with Ang II could increase the levels of MLCK and phosphorylated MLC2 [15] , which suggests that inhibiting Ang II should have decreased MLCK and MLC2 phosphorylation during the early stage of cardiac remodeling. In a recent study, hearts in mice with mutations at the phosphorylation sites of MLCK and MLC2 displayed eccentric hypertrophy as opposed to typical concentric hypertrophy observed in wild-type mice following short-term pressure overload, which indicated that phosphorylated MLC2 is involved in a distinct compensatory hypertrophy response to stress [11] . Four weeks of swimming training increased the levels of MLCK and phosphorylated MLC2 in wild-type mice [13] . Moreover, one week of transaortic constriction induced an evident reduction in the levels of MLCK and phosphorylated MLC2 shortly before compensated cardiac hypertrophy progressed into decompensated cardiac hypertrophy, which occurred between one and two weeks after operation [13] . These data demonstrated that MLC2 phosphorylation plays an important part in adapting to stress and was even increased during the early stages after pressure overload. These results and what was observed in the cultured cardiomyocytes and rat hearts as noted above jointly suggested that Ang II could increase MLCK and MLC2 phosphorylation and promote cardiac remodeling to adapt to pressure overload in an early stage. Therefore, we hypothesized that inhibiting Ang II could suppress the increases of MLCK and phosphorylated MLC2, which would improve cardiac remodeling at an early stage. Consistent with our study, previous studies have also shown that MLC2 phosphorylation is decreased in human heart failure and that MLCK and MLC2 phosphorylation is reduced in mouse hearts subjected to pressure overload [13, 53] . Additionally, the loss of MLCK resulted in profound heart failure after 3 months of pressure overload, and overexpression of MLCK protected against pressure overload-induced cardiac hypertrophy [13] . These results suggested that reducing MLC2 phosphorylation is important for preventing the development of cardiac hypertrophy and heart failure, especially during the cardiac decompensatory stage. Our study has shown that inhibiting Ang II could increase the levels of MLCK and phosphorylated MLC2, which indicated that Ang II could reduce MLCK expression and MLC2 phosphorylation in pressure overload-induced cardiac hypertrophy, especially during the decompensatory stage.
MYPT2 showed no obvious changes after inhibiting Ang II. Therefore, MLCP seemed to be unaffected by Ang II. Although Ang II did not play a direct role in regulating MLCP, cultured cardiomyocytes with adenovirus-mediated overexpression of MYPT2 and PP1cδ could rapidly block the Ang II-induced sarcomere organization [16] . It has been reported that MLC2 could be phosphorylated by MLCK in Ca [20] . Our study revealed that Ang II promoted CaM expression, which may partially account for the increase of phosphorylated MLC2 levels after acute Ang II administration. The expression of CaM was not altered after MMP9 inhibitor treatment, which indicates an undefined relationship between CaM and MMP9.
To explore the molecular mechanisms of how Ang II regulates MLCK, we detected MMP9 expression and found that MMP9 was upregulated in the pressure overload-induced cardiac hypertrophy and downregulated after inhibiting Ang II. To further confirm the role of MMP9, we established an Ang II-induced cardiomyocytes hypertrophic model, and treated these cells with an MMP9 inhibitor. We found MMP9 inhibitor could mitigate cardiomyocyte hypertrophy by decreasing the cell surface area and the mRNA expression of ANP, BNP and β-MHC. Moreover, MMP9 expression was elevated in Ang II-induced cardiomyocyte hypertrophy, and MMP9 inhibitor could increase the levels of MLCK and phosphorylated MLC2 induced by Ang II. Addtionally, recombinant human MLCK was concentration-and time-dependently degraded by recombinant human MMP9 in vitro, and this was prevented by the inhibition of MMP9. It has been reported that MMP9 is involved in the degradation of several kinases [21, 22] . However, our study is the first to demonstrate that MLCK could be degraded by MMP9 in pressure overload-induced cardiac hypertrophy. The mRNA expression of MMP-9 was similar between WT mice and ACE2-knockout mice at 4 weeks of age, while the levels were higher in ACE2-knockout mice at 10 weeks [25] . In addition, MMP9 expression only increased in decompensated mouse hearts at 8 weeks after aortic stenosis [23] . These data suggested that MMP9 did not play a role in cardiac hypertrophy during the early stages but contributes to decompensatory cardiac hypertrophy. This kind of change of MMP9 was in accordance with alterations in the levels of MLCK and phosphorylated MLC2 observed in the pressure overload-induced cardiac hypertrophy, especially during the decompensatory stage. However, the mechanisms of how Ang II regulates the levels of MLCK and phosphorylated MLC2 during the early stages remain unknown and require further studies.
Aortic banding and Ang II infusion are two different methods to establish cardiac hypertrophy and cardiomyocyte hypertrophy separately, which have been reported before [33, 54] . There are a few different mechanisms involved in aortic banding induced cardiac hypertrophy, including the renin-angiotensin-aldosterone system, the adrenergic nervous system, oxidative stress, proinflammatory cytokines, and endothelin [50] . The reninangiotensin-aldosterone system plays an important role in this process, and inhibition of renin-angiotensin system have been shown to markedly attenuate or reverse cardiac remodeling in patients with heart failure and cardiac dilation [7, [47] [48] [49] . Additionally, captopril was able to inhibit the development of cardiac hypertrophy in aortic banded rats [55] , and the same result has been obtained in this animal experiment. Ang II is a key member of the renin-angiotensin-aldosterone axis, and captopril reduced Ang II production by inhibiting angiotensin converting enzyme. These data indirectly indicated that Ang II play an important role in aortic banding induced cardiac hypertrophy. This may be account for why the findings are similar in regarding MLCK, although these two models produce cardiac hypertrophy by different mechanisms. Addtionally, MLCK increased after ACEI reduced Ang II, which implied Ang II could decrease MLCK in aortic banding induced cardiac hypertrophy as well. While It is unclear whether the adrenergic nervous system, oxidative stress, proinflammatory cytokines, and endothelin played a part in expression of MLCK. In addition to elevated Ang II, bradykinin and Ang 1-7 are elevated after aortic banded rats treated with ACEI. But there are no evidences implying that bradykinin and Ang 1-7 are related with expression of MLCK. Meanwhile, Ang II stimulation could alter expression of MLCK in cardiomyocytes and isolated rat heart [15] , and the same result has been obtained in this cell experiment. Further studies will be made to explore whether bradykinin and Ang 1-7 could alter expression of MLCK.
The cardiac functions of all the rats were not monitored at the beginning of the experiment. However, the rats were littermates and assigned to six groups randomly. Furthermore, the investigator was blinded to the rat groups. Based on these conditions, we
